The Experts below are selected from a list of 279 Experts worldwide ranked by ideXlab platform

Qinping Liao - One of the best experts on this subject based on the ideXlab platform.

  • Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness: A Multicenter, Randomized, Controlled, Open-Label, Parallel-Group, Clinical Trial
    2016
    Co-Authors: Qinping Liao
    Abstract:

    Introduction. Atrophic Vaginitis is a common occurrence, particularly among postmenopausal women; however, few seek or receive treatment. One therapeutic solution is topically applied products. Estrogen-based treatments have been shown to be effective; however, many patients are reluctant to use such formulations due to health concerns, hence the need to assess the efficacy of acceptable alternatives. Aim. This multicenter, randomized, controlled, open-label, parallel-group clinical trial set out to evaluate th

  • Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial
    The journal of sexual medicine, 2013
    Co-Authors: Junya Chen, Li Geng, Xuehong Song, Nicola Giordan, Qinping Liao
    Abstract:

    Atrophic Vaginitis is a common occurrence, particularly among postmenopausal women; however, few seek or receive treatment. One therapeutic solution is topically applied products. Estrogen-based treatments have been shown to be effective; however, many patients are reluctant to use such formulations due to health concerns, hence the need to assess the efficacy of acceptable alternatives. This multicenter, randomized, controlled, open-label, parallel-group clinical trial set out to evaluate the efficacy and safety of hyaluronic acid vaginal gel to treat vaginal dryness compared with estriol cream in postmenopausal women. One hundred forty-four subjects were randomized, 72 to the test group treated with hyaluronic acid vaginal gel (Hyalofemme) and 72 to the control group treated with estriol cream (Ovestin). Treatment in both groups was applied by means of a device once every 3 days for a total of 10 applications over 30 days. Efficacy was measured by grading vaginal dryness and three other vaginal symptoms on a visual analog scale. Safety assessments included vital signs, laboratory examinations of the vaginal microecosystem, vaginal pH value, vaginal B ultrasound, and incidence of adverse events. Assessments were performed at baseline, by telephone after the third application, and at the final visit. Both hyaluronic acid vaginal gel and estriol cream can significantly improve the clinical symptoms of vaginal dryness in postmenopausal women, with improvement rate of 84.44% and 89.42%, respectively, after 10 applications, without statistically significant difference between them. Both hyaluronic acid vaginal gel and estriol cream are effective in the treatment of vaginal dryness. Hyaluronic acid vaginal gel may be considered as a valid alternative to estrogen-based treatments in relieving the symptoms of vaginal dryness. © 2013 International Society for Sexual Medicine.

David A Decker - One of the best experts on this subject based on the ideXlab platform.

  • effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with estrogen receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective estrogen receptor modulator (SERM) and VE for 90 days for Atrophic Vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with estrogen receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective estrogen receptor modulator (SERM) and VE for 90 days for Atrophic Vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors taking an aromatase inhibitor or a selective estrogen receptor modulator
    Cancer Research, 2009
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Introduction: Intravaginal estradiol (E2) has been proposed as a safe alternative to systemic estrogen therapy. We report serum E2 levels in breast cancer survivors using either vaginal E2 ring (Estring®) or beta E2 tablet (Vagifem®) while also taking an aromatase inhibitor (AI) or selective estrogen receptor modulator (SERM). These patients are compared to a group of breast cancer survivors using an AI but not taking a VE. Patients and Methods: Postmenopausal women with estrogen receptor positive breast cancer (n=24) using an AI or SERM and vaginal estrogens (VE) to control Atrophic Vaginitis (ring inserted every 90 days; n=10 or 1 tablet inserted 2 x per week; n=14) and 24 control survivors using an AI without VE were enrolled after informed consent. Serum samples were drawn from ring patients pre-insertion and 30 and 60 days post insertion, from tablet patients the morning prior to insertion and 12 hours post insertion, and from controls taking an AI >14 d. Serum samples were assayed for E2 concentrations by highly sensitive radio-immunoassay (Cancer Res 1987;47:1957). Statistical analyses were carried out using SAS® System, v. 9.2. Results: Patient data are provided in tables 1 and 2 (control data not shown). Circulating E2 levels pre-insertion in tablet patients were not significantly different than those in control patients (mean difference=4.7 pmol/l SD:3.2; CI: 2.9-4.9, p=0.48). E2 levels pre-insertion in patients using the ring were significantly greater than controls (mean difference=14.2 pmol/l; SD:7.2;CI, 11-19:p=0.0001). In tablet patients, E2 levels at 12 hours post insertion were 76 pmol/l higher than at pre-insertion baseline (SD:97; CI, 14-89, p Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 806.

Liao Qinping - One of the best experts on this subject based on the ideXlab platform.

  • Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness: A Multicenter, Randomized, Controlled, Open-Label, Parallel-Group, Clinical Trial
    journal of sexual medicine, 2013
    Co-Authors: Chen Junya, Li Geng, Song Xuehong, Li Hongxia, Giordan Nicola, Liao Qinping
    Abstract:

    Introduction Atrophic Vaginitis is a common occurrence, particularly among postmenopausal women; however, few seek or receive treatment. One therapeutic solution is topically applied products. Estrogen-based treatments have been shown to be effective; however, many patients are reluctant to use such formulations due to health concerns, hence the need to assess the efficacy of acceptable alternatives. Aim This multicenter, randomized, controlled, open-label, parallel-group clinical trial set out to evaluate the efficacy and safety of hyaluronic acid vaginal gel to treat vaginal dryness compared with estriol cream in postmenopausal women. Methods One hundred forty-four subjects were randomized, 72 to the test group treated with hyaluronic acid vaginal gel (Hyalofemme) and 72 to the control group treated with estriol cream (Ovestin). Treatment in both groups was applied by means of a device once every 3 days for a total of 10 applications over 30 days. Main Outcome Measures Efficacy was measured by grading vaginal dryness and three other vaginal symptoms on a visual analog scale. Safety assessments included vital signs, laboratory examinations of the vaginal microecosystem, vaginal pH value, vaginal B ultrasound, and incidence of adverse events. Assessments were performed at baseline, by telephone after the third application, and at the final visit. Results Both hyaluronic acid vaginal gel and estriol cream can significantly improve the clinical symptoms of vaginal dryness in postmenopausal women, with improvement rate of 84.44% and 89.42%, respectively, after 10 applications, without statistically significant difference between them. Conclusion Both hyaluronic acid vaginal gel and estriol cream are effective in the treatment of vaginal dryness. Hyaluronic acid vaginal gel may be considered as a valid alternative to estrogen-based treatments in relieving the symptoms of vaginal dryness.Urology & NephrologySCI(E)PubMed2ARTICLE61575-15841

Li Geng - One of the best experts on this subject based on the ideXlab platform.

  • Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial
    The journal of sexual medicine, 2013
    Co-Authors: Junya Chen, Li Geng, Xuehong Song, Nicola Giordan, Qinping Liao
    Abstract:

    Atrophic Vaginitis is a common occurrence, particularly among postmenopausal women; however, few seek or receive treatment. One therapeutic solution is topically applied products. Estrogen-based treatments have been shown to be effective; however, many patients are reluctant to use such formulations due to health concerns, hence the need to assess the efficacy of acceptable alternatives. This multicenter, randomized, controlled, open-label, parallel-group clinical trial set out to evaluate the efficacy and safety of hyaluronic acid vaginal gel to treat vaginal dryness compared with estriol cream in postmenopausal women. One hundred forty-four subjects were randomized, 72 to the test group treated with hyaluronic acid vaginal gel (Hyalofemme) and 72 to the control group treated with estriol cream (Ovestin). Treatment in both groups was applied by means of a device once every 3 days for a total of 10 applications over 30 days. Efficacy was measured by grading vaginal dryness and three other vaginal symptoms on a visual analog scale. Safety assessments included vital signs, laboratory examinations of the vaginal microecosystem, vaginal pH value, vaginal B ultrasound, and incidence of adverse events. Assessments were performed at baseline, by telephone after the third application, and at the final visit. Both hyaluronic acid vaginal gel and estriol cream can significantly improve the clinical symptoms of vaginal dryness in postmenopausal women, with improvement rate of 84.44% and 89.42%, respectively, after 10 applications, without statistically significant difference between them. Both hyaluronic acid vaginal gel and estriol cream are effective in the treatment of vaginal dryness. Hyaluronic acid vaginal gel may be considered as a valid alternative to estrogen-based treatments in relieving the symptoms of vaginal dryness. © 2013 International Society for Sexual Medicine.

  • Evaluation of the Efficacy and Safety of Hyaluronic Acid Vaginal Gel to Ease Vaginal Dryness: A Multicenter, Randomized, Controlled, Open-Label, Parallel-Group, Clinical Trial
    journal of sexual medicine, 2013
    Co-Authors: Chen Junya, Li Geng, Song Xuehong, Li Hongxia, Giordan Nicola, Liao Qinping
    Abstract:

    Introduction Atrophic Vaginitis is a common occurrence, particularly among postmenopausal women; however, few seek or receive treatment. One therapeutic solution is topically applied products. Estrogen-based treatments have been shown to be effective; however, many patients are reluctant to use such formulations due to health concerns, hence the need to assess the efficacy of acceptable alternatives. Aim This multicenter, randomized, controlled, open-label, parallel-group clinical trial set out to evaluate the efficacy and safety of hyaluronic acid vaginal gel to treat vaginal dryness compared with estriol cream in postmenopausal women. Methods One hundred forty-four subjects were randomized, 72 to the test group treated with hyaluronic acid vaginal gel (Hyalofemme) and 72 to the control group treated with estriol cream (Ovestin). Treatment in both groups was applied by means of a device once every 3 days for a total of 10 applications over 30 days. Main Outcome Measures Efficacy was measured by grading vaginal dryness and three other vaginal symptoms on a visual analog scale. Safety assessments included vital signs, laboratory examinations of the vaginal microecosystem, vaginal pH value, vaginal B ultrasound, and incidence of adverse events. Assessments were performed at baseline, by telephone after the third application, and at the final visit. Results Both hyaluronic acid vaginal gel and estriol cream can significantly improve the clinical symptoms of vaginal dryness in postmenopausal women, with improvement rate of 84.44% and 89.42%, respectively, after 10 applications, without statistically significant difference between them. Conclusion Both hyaluronic acid vaginal gel and estriol cream are effective in the treatment of vaginal dryness. Hyaluronic acid vaginal gel may be considered as a valid alternative to estrogen-based treatments in relieving the symptoms of vaginal dryness.Urology & NephrologySCI(E)PubMed2ARTICLE61575-15841

Elizabeth Folkerd - One of the best experts on this subject based on the ideXlab platform.

  • effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with estrogen receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective estrogen receptor modulator (SERM) and VE for 90 days for Atrophic Vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator
    Journal of Oncology Practice, 2012
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Background: Intravaginal estradiols (VE) have been proposed as safe alternatives to systemic estrogen therapy in breast cancer survivors. Patients and Methods: Postmenopausal women with estrogen receptor–positive breast cancer or at high risk for breast cancer (n 24) who were taking an aromatase inhibitor (AI) or a selective estrogen receptor modulator (SERM) and VE for 90 days for Atrophic Vaginitis and 24 controls taking AI only participated in the study. Serum samples were drawn from VE ring patients before insertion and 30 and 60 days postinsertion, from VE tablet patients the morning before insertion and approximately 12 hours postinsertion, and once from controls. Samples were assayed for E2 concentrations by using highly sensitive radioimmunoassay after ether extraction.

  • effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors taking an aromatase inhibitor or a selective estrogen receptor modulator
    Cancer Research, 2009
    Co-Authors: S M Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F Hayes, David A Decker
    Abstract:

    Introduction: Intravaginal estradiol (E2) has been proposed as a safe alternative to systemic estrogen therapy. We report serum E2 levels in breast cancer survivors using either vaginal E2 ring (Estring®) or beta E2 tablet (Vagifem®) while also taking an aromatase inhibitor (AI) or selective estrogen receptor modulator (SERM). These patients are compared to a group of breast cancer survivors using an AI but not taking a VE. Patients and Methods: Postmenopausal women with estrogen receptor positive breast cancer (n=24) using an AI or SERM and vaginal estrogens (VE) to control Atrophic Vaginitis (ring inserted every 90 days; n=10 or 1 tablet inserted 2 x per week; n=14) and 24 control survivors using an AI without VE were enrolled after informed consent. Serum samples were drawn from ring patients pre-insertion and 30 and 60 days post insertion, from tablet patients the morning prior to insertion and 12 hours post insertion, and from controls taking an AI >14 d. Serum samples were assayed for E2 concentrations by highly sensitive radio-immunoassay (Cancer Res 1987;47:1957). Statistical analyses were carried out using SAS® System, v. 9.2. Results: Patient data are provided in tables 1 and 2 (control data not shown). Circulating E2 levels pre-insertion in tablet patients were not significantly different than those in control patients (mean difference=4.7 pmol/l SD:3.2; CI: 2.9-4.9, p=0.48). E2 levels pre-insertion in patients using the ring were significantly greater than controls (mean difference=14.2 pmol/l; SD:7.2;CI, 11-19:p=0.0001). In tablet patients, E2 levels at 12 hours post insertion were 76 pmol/l higher than at pre-insertion baseline (SD:97; CI, 14-89, p Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 806.

  • caution vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors
    Annals of Oncology, 2006
    Co-Authors: Anne Kendall, Elizabeth Folkerd, Mitch Dowsett, Ian E Smith
    Abstract:

    Background: Aromatase inhibitors (AI) are increasingly used in early breast cancer and there is a growing interest in associated long-term side-effects of profound estrogen suppression. Urogenital side-effects due to Atrophic Vaginitis are often managed with vaginal estrogen preparations. These are generally perceived to result in minimal systemic absorption of estrogen. We followed serum estradiol, follicle stimulating hormone (FSH) and luteinising hormone (LH) levels in seven postmenopausal women using vaginal estrogen preparations whilst on AIs for breast cancer. Patients and methods: Serum was analysed for estradiol, FSH and LH at baseline then 2, 4, 7–10 and 12 weeks since commencement of vaginal estradiol. Estradiol was measured on an assay specifically developed for measuring low levels in postmenopausal women. Results: Serum estradiol levels rose from baseline levels £5 pmol/l consistent with AI therapy to a mean 72 pmol/l at 2 weeks. By 4 weeks this had decreased to <35 pmol/l in the majority (median 16 pmol/l) although significant further rises were seen in two women. Conclusions: The vaginal estradiol tablet Vagifem significantly raises systemic estradiol levels, at least in the short term. This reverses the estradiol suppression achieved by aromatase inhibitors in women with breast cancer and is contraindicated.